Klotho Neurosciences to Acquire Longevity Therapeutic Assets from Turn Biotechnologies

Klotho Neurosciences, Inc. has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc., a company focused on induced pluripotent stem cells (iPSC) and cellular reprogramming. The proposed transaction is subject to customary closing conditions. 

Under the LOI, Klotho would acquire Turn’s ERA (Epigenetic Reprogramming of Age) platform and eTurna RNA delivery system. These technologies are designed to rejuvenate somatic cells and restore tissue function, creating opportunities for a long list of regenerative therapies in dermatology, ophthalmology, immunology, osteoarthritis, muscle health and diseases like amyotrophic lateral sclerosis (ALS).

As part of this transaction, Klotho will be acquiring a signed out-licensing and co-development partnership with a leading South Korean pharmaceutical company worth up to $300 million. This global partnership underscores the commercial interest in Turn’s platform and highlights the broad potential applications of its technology.

“This LOI marks a transformative step for Klotho,” said Dr. Joseph Sinkule, CEO of Klotho Neurosciences. “The Klotho gene is often referred to as the ‘anti-aging gene,’ first identified for its ability to extend lifespan in animal models and protect against neurodegenerative diseases. Our company was founded on translating that science into therapies that combat age-related decline. By adding Turn’s ERA technology — which leverages six RNA molecules, including four of the Yamanaka transcription factors that can reset cellular age — together with the eTurna RNA lipid nanoparticle (LNP) delivery platform, we are expanding beyond a single Klotho gene into a powerful system of cellular rejuvenation. Coupled with Turn’s pharma partnership, this combination demonstrates both the scientific foundation and the commercial interest that position Klotho to pioneer therapies extending healthspan and addressing diseases of aging — from Alzheimer’s and Parkinson’s to skin, muscle, bone, and vision loss.”

Upon completion of the contemplated transaction, Klotho plans to rebrand to reflect its broadened mission and expanded therapeutic reach. Klotho also intends to bring over key members of Turn’s management and R&D teams post-close.